Keywords: CR; complete response; DEE; drug-eluting embolic; ÎPBV; change in median parenchymal blood volume; HCC; hepatocellular carcinoma; mRECIST; modified Response Evaluation Criteria In Solid Tumors; PBV; parenchymal blood volume; PD; progressive disease; PR;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: CI; confidence interval; CR; complete response; DEE; drug-eluting embolic; EASL; European Association for the Study of the Liver; HCC; hepatocellular carcinoma; mRECIST; modified Response Evaluation Criteria In Solid Tumors; PEG; polyethylene glycol; PR;
Keywords: CI; confidence interval; mRECIST; modified Response Evaluation Criteria in Solid Tumors; RCC; renal cell carcinoma; 90Y; yttrium-90;
Keywords: TACE; Transarterial Chemoembolization; cTACE; conventional Transarterial Chemoembolization; HCC; hepatocellular carcinoma; EASL; European Association for the Study of the Liver Guidelines; qEASL; 3D quantitative European Association for the Study of the L
Keywords: CI; confidence interval; HCC; hepatocellular carcinoma; HR; hazard ratio; INR; international normalization ratio; mRECIST; modified response evaluation criteria in solid tumor;
Keywords: Transarterial therapy; follow-up; hepatic malignancy; survey; IO; Interventional Oncology; IR; Interventional Radiology; LRT; locoregional therapy; SIR; Society of Interventional Radiology; CT; computed tomography; TACE; transarterial chemoembolization; c
Keywords: SBRT; stereotactic body radiation therapy; HCC; hepatocellular carcinoma; RECIST; response evaluation criteria in solid tumors; CTCAE; common terminology criteria for adverse events; LC; local control; OS; overall survival; PFS; progression-free survival;
Keywords: Outcome; Liver Cancer; Therapy; Hepatic; AUROC; BCLC; Barcelona Clinic Liver Cancer; CI; confidence interval; HAP; hepatic arterial embolization prognostic; HCC; hepatocellular carcinoma; HR; hazard ratio; mHAP; modified hepatic arterial embolization prog
Keywords: HCC; hepatocellular carcinoma; TACE; transarterial chemoembolization; OS; overall survival; EASL; European Association for the Study of the Liver; mRECIST; modified Response Evaluation Criteria in Solid Tumors; CT; computed tomography; CR; complete respon
Keywords: CI; confidence interval; CR; complete response; CTP; Child-Turcotte-Pugh; DFS; disease-free survival; HCC; hepatocellular carcinoma; MELD; Model for End-Stage Liver Disease; mRECIST; modified Response Evaluation Criteria In Solid Tumors; SBRT; stereot
Keywords: AFP; α-fetoprotein; AUC; area under the curve; BCLC; Barcelona Clinic Liver Cancer; HCC; hepatocellular carcinoma; IL; interleukin; mRECIST; modified Response Evaluation Criteria In Solid Tumors; NLR; neutrophil-to-lymphocyte ratio; RE; radioembolization
Keywords: mRECIST; EASL; Overall survival; Prediction; Equivalence;
Dual-Energy CT-Derived Volumetric Iodine Concentration for the Assessment of Therapeutic Response after Microwave Ablation in a Rabbit Model with Intrahepatic VX2 Tumor
Keywords: HCC; hepatocellular carcinoma; ICC; intraclass correlation coefficient; mRECIST; modified Response Evaluation Criteria In Solid Tumors; MW; microwave; VIC; volumetric iodine concentration;
Multicenter Phase II Clinical Trial of Sorafenib Combined with Transarterial Chemoembolization for Advanced Stage Hepatocellular Carcinomas (Barcelona Clinic Liver Cancer Stage C): STAB Study
Keywords: AE; adverse event; AFP; alpha fetoprotein; ALT; alanine aminotransferase; AST; aspartate aminotransferase; CI; confidence interval; HCC; hepatocellular carcinoma; mRECIST; modified Response Evaluation Criteria in Solid Tumors; OS; overall survival; PVTT;
Effects of Reduction in Tumor Burden on Survival in Epithelioid Malignant Pleural Mesothelioma
Keywords: CR; complete response; FDA; Food and Drug Administration; HR; hazard ratio; MPM; malignant pleural mesothelioma; mRECIST; modified pleural Response Evaluation Criteria in Solid Tumors; ORR; objective response rate; OS; overall survival; PD; progression of
Progression of Treated versus Untreated Liver Imaging Reporting and Data System Category 4 Masses after Transcatheter Arterial Embolization Therapy
Keywords: APHE; arterial phase hyperenhancing; CI; confidence interval; HCC; hepatocellular carcinoma; LI-RADS; Liver Imaging Reporting and Data System; LR; LI-RADS category; mRECIST; modified Response Evaluation Criteria in Solid Tumors;
Hepatocellular carcinoma treated with sorafenib: Arterial tumor perfusion in dynamic contrast-enhanced CT as early imaging biomarkers for survival
Keywords: HCC; hepatocellular carcinoma; CT; computed tomography; MRI; magnetic resonance imaging; mRECIST; modified response evaluation criteria in solid tumors; TACE; transarterial chemoembolization; HAIC; hepatic arterial infusion chemotherapy; ECOG PS; eastern
Radiation Segmentectomy versus Selective Chemoembolization in the Treatment of Early-Stage Hepatocellular Carcinoma
Keywords: CI; confidence interval; CR; complete response; HCC; hepatocellular carcinoma; HR; hazard ratio; IQR; interquartile range; mRECIST; modified Response Evaluation Criteria In Solid Tumors; PR; partial response; PSM; propensity score matching; RS; radiation
Evaluation of response after SBRT for liver tumors
Keywords: SBRT; stereotactic body radiotherapy; RECIST; criteria of response in solid tumors; mRECIST; modified criteria of response in solid tumors; CT; computerized tomography; MRI; magnetic resonance imaging; PET; positron-emission tomography; HCC; Hepatocellula
Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma
Keywords: FDG-PET; 18F-fluorodeoxyglucose positron emission tomography; MPM; Malignant Pleural Mesothelioma; mRECIST; Modified Response Evaluation Criteria in Solid Tumors, Metabolic Response; Chemotherapy; Malignant pleural mesothelioma; Metabolic response; mRECIS
Early response evaluation using CT-perfusion one day after transarterial chemoembolization for HCC predicts treatment response and long-term disease control
Keywords: ALP; arterial liver perfusion; BF; blood flow; BV; blood volume; CR; complete response; CTP; CT perfusion; HCC; hepatocellular carcinoma; HPI; hepatic perfusion index; MDCT; multidetector computed tomography; mRECIST; modified response criteria in solid t
Transarterial Chemoembolization with Small Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: Experience from a Cohort of 421 Patients at an Italian Center
Keywords: BCLC; Barcelona Clinic Liver Cancer; CI; confidence interval; DEE; drug-eluting embolic; EASL; European Association for the Study of the Liver; HCC; hepatocellular carcinoma; mRECIST; modified Response Evaluation Criteria In Solid Tumors; ORR; overall res
Tumor Dose Response in Yttrium-90 Resin Microsphere Embolization for Neuroendocrine Liver Metastases: A Tumor-Specific Analysis with Dose Estimation Using SPECT-CT
Keywords: CR; complete response; HCC; hepatocellular carcinoma; LSF; lung shunt fraction; mRECIST; Modified Response Evaluation Criteria in Solid Tumors; NET; neuroendocrine tumor; PD; progressive disease; PR; partial response; SD; stable disease; SPECT; single pho
The Role of Dual-Phase Cone-Beam CT in Predicting Short-Term Response after Transarterial Chemoembolization for Hepatocellular Carcinoma
Keywords: CI; confidence interval; CR; complete response; HCC; hepatocellular carcinoma; HU; Hounsfield unit; mRECIST; modified Response Evaluation Criteria in Solid Tumors; PD; progressive disease; PR; partial response; ROI; region of interest; SD; stable disease;
Transarterial Chemoembolization of Renal Cell Carcinoma: A Prospective Controlled Trial
Keywords: DEE; drug-eluting embolic; mRECIST; modified Response Evaluation Criteria In Solid Tumors; NSS; nephron-sparing surgery; RCC; renal cell carcinoma; RN; radical nephrectomy; TAE; transarterial embolization; VAS; visual analog scale;
Modified Response Evaluation Criteria in Solid Tumors and European Association for the Study of the Liver Criteria Using Delayed-Phase Imaging at an Early Time Point Predict Survival in Patients with Unresectable Intrahepatic Cholangiocarcinoma following
Keywords: CR; complete response; EASL; European Association for the Study of the Liver; ICC; intrahepatic cholangiocarcinoma; mRECIST; modified Response Evaluation Criteria In Solid Tumors; PD; progressive disease; PR; partial response; RECIST; Response Evaluation
Correlation of Technetium-99m Macroaggregated Albumin and Yttrium-90 Glass Microsphere Biodistribution in Hepatocellular Carcinoma: A Retrospective Review of Pretreatment Single Photon Emission CT and Posttreatment Positron Emission Tomography/CT
Keywords: AD; absorbed dose; CI; confidence interval; HCC; hepatocellular carcinoma; MAA; macroaggregated albumin; mRECIST; modified RECIST; PET; positron emission tomography; RDC; reproducibility coefficient; RE; radioembolization; RECIST; Response Evaluation Crit
Radioembolization of Hepatic Malignancies: Background, Quality Improvement Guidelines, and Future Directions
Keywords: AFP; α-fetoprotein; ECOG; Eastern Cooperative Oncology Group; EASL; European Association for Study of the Liver; FDA; Food and Drug Administration; FDG; fluorodeoxyglucose; HCC; hepatocellular carcinoma; MAA; macroaggregated albumin; mRECIST; modified Re
EUS-guided paclitaxel injection as an adjunctive therapy to systemic chemotherapy and concurrent external beam radiation before surgery for localized or locoregional esophageal cancer: a multicenter prospective randomized trial
Keywords: 5-FU; 5-fluorouracil; AE; adverse event; CI; confidence interval; CR; complete response; CRT; chemoradiotherapy; DLT; dose-limiting toxicity; ECOG; Eastern Cooperative Oncology Group; KPS; Karnofsky Performance Status; mITT; modified intention to treat; m
Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology
Keywords: RECIST; EASL criteria; mRECIST; Image subtraction; Diffusion-weighted imaging;
Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases
Keywords: CNS; central nervous system; K-RAS; Kirsten rat sarcoma; mRECIST; modified Response Evaluation Criteria in Solid Tumors; MRI; magnetic resonance imaging; NSCLC; non-small cell lung cancer; pts; patients; PET-CT; positron emission tomography-computer tomog
Percutaneous Ablation of Hepatic Tumors Using Irreversible Electroporation: A Prospective Safety and Midterm Efficacy Study in 34 Patients
Keywords: CTCAE; Common Terminology Criteria for Adverse Events; IRE; irreversible electroporation; LRFS; local recurrence-free survival; mRECIST; modified Response Evaluation Criteria In Solid Tumors;
CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus
Keywords: Hepatocellular carcinoma; Anti-angiogenic therapy; Tumoral response assessment; RECIST 1.1; mRECIST; Choi;
Diffusion-Weighted MR Imaging of Hepatocellular Carcinoma: Current Value in Clinical Evaluation of Tumor Response to Locoregional Treatment
Keywords: ADC; apparent diffusion coefficient; DWI; diffusion-weighted imaging; EASL; European Association for the Study of the Liver; EPI; echoplanar imaging; HCC; hepatocellular carcinoma; LRT; locoregional therapy; mRECIST; modified Response Evaluation Criteria
Transcatheter Therapy for Hepatic Malignancy: Standardization of Terminology and Reporting Criteria
Keywords: CR; complete response, EASL = European Association for the Study of the Liver; HCC; hepatocellular carcinoma; MAA; macroaggregated albumin; mRECIST; modified Response Evaluation Criteria In Solid Tumors; PET; positron emission tomography; PFS; progression
Irreversible Electroporation Can Effectively Ablate Hepatocellular Carcinoma to Complete Pathologic Necrosis
Keywords: HCC; hepatocellular carcinoma; IRE; irreversible electroporation; mRECIST; Response Evaluation Criteria In Solid Tumors;
Transarterial chemoembolization in soft-tissue sarcoma metastases to the liver - The use of imaging biomarkers as predictors of patient survival
Keywords: Liver cancer; Sarcoma; Transarterial chemoembolization; Volumetry; MRI; RECIST; mRECIST; EASL; mSTS; metastatic soft-tissue sarcoma; qEASL; quantitative European Association for the Study of the Liver; RECIST; Response Evaluation Criteria in Solid Tumors;
Safety and Efficacy of 70-150 μm and 100-300 μm Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma
Keywords: BCLC; Barcelona Clinic Liver Cancer; DEB; drug-eluting bead; DEE; drug-eluting embolic; HCC; hepatocellular carcinoma; mRECIST; modified Response Evaluation Criteria In Solid Tumors;
Liver, Pancreas and Biliary TractInter-observer variability of response evaluation criteria for hepatocellular carcinoma treated with chemoembolization
Keywords: EASL; Hepatocellular carcinoma; Inter-observer variability; mRECIST; Treatment response;
ReviewTransarterial chemoembolization: Modalities, indication, and patient selection
Keywords: TACE; HCC; Patient selection; Response; mRECIST; Overall survival; Hepatocellular carcinoma; Intermediate stage;
Research ArticleOptimal methods for measuring eligibility for liver transplant in hepatocellular carcinoma patients undergoing transarterial chemoembolization
Keywords: LT; liver transplantation; HCC; hepatocellular carcinoma; TACE; transarterial chemoembolization; CT; computed tomography; RECIST; Response Evaluation Criteria In Solid Tumors; mRECIST; modified Response Evaluation Criteria In Solid Tumors; IQR; interquart
Yttrium-90 Glass-Based Microsphere Radioembolization in the Treatment of Hepatocellular Carcinoma Secondary to the Hepatitis B Virus: Safety, Efficacy, and Survival
Keywords: AFP; α-fetoprotein; BCLC; Barcelona Clinic Liver Cancer; CI; confidence interval; ECOG; Eastern Cooperative Oncology Group; HBV; hepatitis B virus; HBV-HCC; hepatocellular carcinoma resulting from hepatitis B virus etiology; HCC; hepatocellular carcinoma
Baseline and Early MR Apparent Diffusion Coefficient Quantification as a Predictor of Response of Unresectable Hepatocellular Carcinoma to Doxorubicin Drug-Eluting Bead Chemoembolization
Keywords: ADC; apparent diffusion coefficient; AUC; area under the curve; CR; complete response; DEB; drug-eluting bead; DWI; diffusion-weighted imaging; EASL; European Association for the Study of the Liver; HCC; hepatocellular carcinoma; LRT; locoregional therapy
Degradable Starch Microspheres versus Ethiodol and Doxorubicin in Transarterial Chemoembolization of Hepatocellular Carcinoma
Keywords: ALT; alanine aminotransferase; AST; aspartate aminotransferase; BCLC; Barcelona Clinic Liver Cancer; DSM; degradable starch microsphere; HCC; hepatocellular carcinoma; mRECIST; modified Response Evaluation Criteria In Solid Tumors;
Transcatheter Arterial Chemoembolization with Doxorubicin-Eluting Superabsorbent Polymer Microspheres in the Treatment of Hepatocellular Carcinoma: Midterm Follow-up
Keywords: BCLC; Barcelona Clinic Liver Class; HCC; hepatocellular carcinoma; mRECIST; modified Response Evaluation Criteria In Solid Tumors; OLT; orthotopic liver transplantation; SAE; serious adverse event; SAP; superabsorbent polymer;
Serum MicroRNA-210 as a Predictive Biomarker for Treatment Response and Prognosis in Patients with Hepatocellular Carcinoma undergoing Transarterial Chemoembolization
Keywords: AFP; α-fetoprotein; BCLC; Barcelona Clinic Liver Cancer; CR; complete response; HCC; hepatocellular carcinoma; miRNA; microRNA; miR-210; microRNA-210; mRECIST; modified Response Evaluation Criteria in Solid Tumors; OS; overall survival; PD; progressive d
Research ArticleComparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization
Keywords: EASL; European Association for the Study of the Liver; RECIST; Response Evaluation Criteria in Solid Tumors; mRECIST; modified RECIST; WHO; World Health Organization; HCC; hepatocellular carcinoma; TACE; transarterial chemoembolization; BCLC; Barcelona Cl
Transarterial Chemoembolization with Drug-eluting Beads in Hepatocellular Carcinoma: Usefulness of Contrast Saturation Features on Cone-Beam Computed Tomography Imaging for Predicting Short-term Tumor Response
Keywords: CR; complete response; DEB; drug-eluting bead; HCC; hepatocellular carcinoma; mRECIST; modified Response Evaluation Criteria for Solid Tumors; PD; progressive disease; PR; partial response; SD; stable disease;
Cancer Concepts and Principles: Primer for the Interventional Oncologist-Part I
Keywords: CR; complete response; DCR; disease control rate; EASL; European Association for the Study of the Liver; FDA; Food and Drug Administration; HCC; hepatocellular carcinoma; mRECIST; modified Response Evaluation Criteria in Solid Tumors; NCCN; National Compr
Single-center Comparison of Three Chemoembolization Regimens for Hepatocellular Carcinoma
Keywords: CDM; cisplatin/doxorubicin/mitomycin-c/ethiodized oil; CR; complete response; DE; doxorubicin/ethiodized oil; DEB; drug-eluting bead; HCC; hepatocellular carcinoma; mRECIST; modified Response Evaluation Criteria in Solid Tumors; PACS; picture archiving an